An in vivo platform to jointly monitor cellular and metabolic responses to chemotherapy.
Pister, V.; Tatarova, Z.; Park, N.; Gaidhani, G.; Jakubik, J.; Heiser, L.; Blum, J.; Palmiotti, A.; Maloney, E.; Fraenkel, E.; Davidson, S.; Jonas, O.
Show abstract
How drug treatments reshape immune and metabolic states within intact tumors remains difficult to study with existing methods. We introduce a spatial pharmacology platform that enables parallel analysis of multiple agents within a single tumor, linking local drug exposure to immune and metabolic remodeling. Using a microdevice for localized drug delivery, we created a large-scale paired CyCIF-MALDI dataset spanning 1.5 million cells across 27 MMTV-PyMT tumor sections and nine treatment programs, enabling integrated spatial pharmacology at unprecedented scale. Metabolic signatures robustly predict proteomic spatial neighborhoods establishing metabolism as a powerful predictor of tumor organization and immune phenotype. Within this framework, we identify a dominant metabolic axis defined by the myeloid polarization between CSF1R+ tumor-associated macrophages and MPO+ infiltrating myeloid cells localized near regions of drug-induced tumor cell death. Finally, we detect putative lipid-associated macrophage (LAM)-like populations within drug-resistant treatment regions.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.